{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:17Z","timestamp":1792784897556,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Drug Program of China"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871003"],"award-info":[{"award-number":["31871003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z201100006820005"],"award-info":[{"award-number":["Z201100006820005"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Small interfering RNA (siRNA) constitutes a promising therapeutic modality supporting the potential functional cure of hepatitis B. A novel ionizable lipidoid nanoparticle (RBP131) and a state-of-the-art lyophilization technology were developed in this study, enabling to deliver siRNA targeting apolipoprotein B (APOB) into the hepatocytes with an ED\n                    <jats:sub>50<\/jats:sub>\n                    of 0.05\u2009mg\/kg after intravenous injection. In addition, according to the requirements of Investigational New Drug (IND) application, a potent siRNA targeting hepatitis B virus (HBV) was selected and encapsulated with RBP131 to fabricate a therapeutic formulation termed RB-HBV008. Efficacy investigations in transient and transgenic mouse models revealed that the expressions of viral RNAs and antigens (HBsAg and HBeAg), as well as viral DNA, were repressed, dose-dependently and time-dependently at multilog decreasing amplitude, in both circulation and liver tissue. In contrast, entecavir (ETV), the first-line clinically-employed nucleoside analog drug, barely recused the antigen expression, although it triggered as high as 3.50\u2009log reduction of viral DNA, in line with clinical observations. Moreover, the toxicity profiles suggested satisfactory safety outcomes with ten times the therapeutic window. Therefore, this study provides an effective nucleic acid delivery system and a promising RNAi agent for the treatment of hepatitis B.\n                  <\/jats:p>","DOI":"10.1038\/s41392-021-00859-y","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:02:42Z","timestamp":1644523362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-7245","authenticated-orcid":false,"given":"Yuanyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Mollerat du Jeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"859_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/liv.13656","volume":"38","author":"RF Schinazi","year":"2018","unstructured":"Schinazi, R. F., Ehteshami, M., Bassit, L. & Asselah, T. Towards HBV curative therapies. Liver Int. 38, 102\u2013114 (2018).","journal-title":"Liver Int."},{"key":"859_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang, L. S. Y., Covert, E., Wilson, E. & Kottilil, S. Chronic Hepatitis B infection: a review. JAMA 319, 1802\u20131813 (2018).","journal-title":"JAMA"},{"key":"859_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto, W. K., Lo, Y. R., Pawlotsky, J. M. & Yuen, M. F. Chronic hepatitis B virus infection. Lancet 392, 2313\u20132324 (2018).","journal-title":"Lancet"},{"key":"859_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bpg.2017.04.013","volume":"31","author":"ZS Valaydon","year":"2017","unstructured":"Valaydon, Z. S. & Locarnini, S. A. The virological aspects of hepatitis B. Best. Pr. Res Clin. Gastroenterol. 31, 257\u2013264 (2017).","journal-title":"Best. Pr. Res Clin. Gastroenterol."},{"key":"859_CR5","doi-asserted-by":"publisher","unstructured":"Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aan0241 (2017).","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong, S. & Revill, P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol. 64, S4\u2013S16 (2016).","journal-title":"J. Hepatol."},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","volume":"30","author":"C Dembek","year":"2018","unstructured":"Dembek, C., Protzer, U. & Roggendorf, M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr. Opin. Virol. 30, 58\u201367 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"859_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/mt.2013.31","volume":"21","author":"CI Wooddell","year":"2013","unstructured":"Wooddell, C. I. et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973\u2013985 (2013).","journal-title":"Mol. Ther."},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu, B. et al. Therapeutic siRNA: state of the art. Signal Transduct. Target Ther. 5, 101 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"859_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"Y Weng","year":"2019","unstructured":"Weng, Y. et al. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. 37, 801\u2013825 (2019).","journal-title":"Biotechnol. Adv."},{"key":"859_CR11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.cclet.2020.09.010","volume":"32","author":"K Li","year":"2021","unstructured":"Li, K., Lu, M., Xia, X. & Huang, Y. Recent advances in photothermal and RNA interfering synergistic therapy. Chin. Chem. Lett. 32, 1010\u20131016 (2021).","journal-title":"Chin. Chem. Lett."},{"key":"859_CR12","first-page":"165","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Interference of miR-107 with Atg12 is inhibited by HULC to promote metastasis of hepatocellular carcinoma. MedComm (2020) 1, 165\u2013177 (2020).","journal-title":"MedComm (2020)"},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1021\/acsbiomaterials.1c00765","volume":"7","author":"K Li","year":"2021","unstructured":"Li, K. et al. Progress of photodynamic and RNAi combination therapy in cancer treatment. ACS Biomater. Sci. Eng. 7, 4420\u20134429 (2021).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"859_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-0716-1298-9_6","volume":"2282","author":"M Lu","year":"2021","unstructured":"Lu, M., Zhang, M., Hu, B. & Huang, Y. siRNA design and GalNAc-empowered hepatic targeted delivery. Methods Mol. Biol. 2282, 77\u2013100 (2021).","journal-title":"Methods Mol. Biol."},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"2006515","DOI":"10.1002\/adfm.202006515","volume":"30","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Viral protein-pseudotyped and siRNA-electroporated extracellular vesicles for cancer immunotherapy. Adv. Funct. Mater. 30, 2006515 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"859_CR16","doi-asserted-by":"publisher","first-page":"10939","DOI":"10.1039\/D0NR00301H","volume":"12","author":"D Zhao","year":"2020","unstructured":"Zhao, D. et al. A photo-triggerable aptamer nanoswitch for spatiotemporal controllable siRNA delivery. Nanoscale 12, 10939\u201310943 (2020).","journal-title":"Nanoscale"},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"119925","DOI":"10.1016\/j.biomaterials.2020.119925","volume":"242","author":"M Lu","year":"2020","unstructured":"Lu, M. & Huang, Y. Bioinspired exosome-like therapeutics and delivery nanoplatforms. Biomaterials 242, 119925 (2020).","journal-title":"Biomaterials"},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2019.08.021","volume":"311-312","author":"Z Zheng","year":"2019","unstructured":"Zheng, Z. et al. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J. Control Release 311-312, 43\u201349 (2019).","journal-title":"J. Control Release"},{"key":"859_CR19","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cclet.2020.12.005","volume":"32","author":"D Yin","year":"2021","unstructured":"Yin, D. et al. Shear-responsive peptide\/siRNA complexes as lung-targeting gene vectors. Chin. Chem. Lett. 32, 1731\u20131736 (2021).","journal-title":"Chin. Chem. Lett."},{"key":"859_CR20","doi-asserted-by":"publisher","first-page":"20210153","DOI":"10.1002\/EXP.20210153","volume":"1","author":"HW An","year":"2021","unstructured":"An, H. W. et al. Rationally designed modular drug delivery platform based on intracellular peptide self\u2010assembly. Exploration 1, 20210153 (2021).","journal-title":"Exploration"},{"key":"859_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.omtn.2018.08.003","volume":"12","author":"S Zheng","year":"2018","unstructured":"Zheng, S. et al. siRNA knockdown of RRM2 effectively suppressed pancreatic tumor growth alone or synergistically with doxorubicin. Mol. Ther. Nucleic Acids 12, 805\u2013816 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1021\/acs.nanolett.0c04468","volume":"21","author":"C Li","year":"2021","unstructured":"Li, C. et al. Core role of hydrophobic core of polymeric nanomicelle in endosomal escape of siRNA. Nano Lett. 21, 3680\u20133689 (2021).","journal-title":"Nano Lett."},{"key":"859_CR23","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1021\/acs.nanolett.8b02553","volume":"18","author":"T Zhang","year":"2018","unstructured":"Zhang, T. et al. Fluorinated oligoethylenimine nanoassemblies for efficient siRNA-mediated gene silencing in serum-containing media by effective endosomal escape. Nano Lett. 18, 6301\u20136311 (2018).","journal-title":"Nano Lett."},{"key":"859_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cclet.2020.11.024","volume":"32","author":"S Guo","year":"2021","unstructured":"Guo, S. et al. A novel polyethyleneimine-decorated FeOOH nanoparticle for efficient siRNA delivery. Chin. Chem. Lett. 32, 102\u2013106 (2021).","journal-title":"Chin. Chem. Lett."},{"key":"859_CR25","doi-asserted-by":"publisher","first-page":"32289","DOI":"10.1021\/acsami.0c06614","volume":"12","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. ROS-activatable siRNA-engineered polyplex for NIR-triggered synergistic cancer treatment. ACS Appl Mater. Interfaces 12, 32289\u201332300 (2020).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"859_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.bioactmat.2021.05.051","volume":"9","author":"C Li","year":"2022","unstructured":"Li, C. et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact. Mater. 9, 590\u2013601 (2022).","journal-title":"Bioact. Mater."},{"key":"859_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/EXP.20210008","volume":"1","author":"S Guo","year":"2021","unstructured":"Guo, S. et al. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment. Exploration 1, 35\u201349 (2021).","journal-title":"Exploration"},{"key":"859_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.bioactmat.2020.07.003","volume":"5","author":"T Yang","year":"2020","unstructured":"Yang, T. et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact. Mater. 5, 1053\u20131061 (2020).","journal-title":"Bioact. Mater."},{"key":"859_CR29","doi-asserted-by":"publisher","first-page":"9706","DOI":"10.1021\/acs.nanolett.1c03539","volume":"21","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Intercalation-driven formation of siRNA nanogels for cancer therapy. Nano Lett. 21, 9706\u20139714 (2021).","journal-title":"Nano Lett."},{"key":"859_CR30","doi-asserted-by":"publisher","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci Adv. 6, eabc7031 (2020).","journal-title":"Sci Adv."},{"key":"859_CR31","doi-asserted-by":"publisher","first-page":"101017","DOI":"10.1016\/j.nantod.2020.101017","volume":"36","author":"T Yang","year":"2021","unstructured":"Yang, T. et al. Rolling microneedle electrode array (RoMEA) empowered nucleic acid delivery and cancer immunotherapy. Nano Today 36, 101017 (2021).","journal-title":"Nano Today"},{"key":"859_CR32","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.7150\/thno.23438","volume":"8","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array. Theranostics 8, 2361\u20132376 (2018).","journal-title":"Theranostics"},{"key":"859_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.omtn.2019.12.004","volume":"19","author":"Y Weng","year":"2020","unstructured":"Weng, Y. et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol. Ther. Nucleic Acids 19, 581\u2013601 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"859_CR34","first-page":"1","volume":"WO2016206626","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Gao, S. & Huang, Y. siRNA, pharmaceutical composition and conjugate which contain siRNA, and uses thereof. World Intellect. Prop. Organ. WO2016206626, 1\u201347 (2016).","journal-title":"World Intellect. Prop. Organ."},{"key":"859_CR35","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"859_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).","journal-title":"Nat. Commun."},{"key":"859_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","volume":"1510","author":"SC Semple","year":"2001","unstructured":"Semple, S. C. et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510, 152\u2013166 (2001).","journal-title":"Biochim. Biophys. Acta"},{"key":"859_CR38","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.7150\/thno.15246","volume":"6","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues. Theranostics 6, 1528\u20131541 (2016).","journal-title":"Theranostics"},{"key":"859_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998\u20131006 (2010).","journal-title":"Lancet"},{"key":"859_CR40","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","volume":"126","author":"EA Stein","year":"2012","unstructured":"Stein, E. A. et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283\u20132292 (2012).","journal-title":"Circulation"},{"key":"859_CR41","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Patisiran: first global approval. Drugs 78, 1625\u20131631 (2018).","journal-title":"Drugs"},{"key":"859_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"859_CR43","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1073\/pnas.1322937111","volume":"111","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955\u20133960 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"859_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty, R. L., Whitehead, K. A., Vegas, A. J. & Anderson, D. G. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol. Ther. 20, 513\u2013524 (2012).","journal-title":"Mol. Ther."},{"key":"859_CR45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/gt.2008.60","volume":"15","author":"E Wisse","year":"2008","unstructured":"Wisse, E. et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193\u20131199 (2008).","journal-title":"Gene Ther."},{"key":"859_CR46","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.3865369","volume":"230","author":"FV Chisari","year":"1985","unstructured":"Chisari, F. V. et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230, 1157\u20131160 (1985).","journal-title":"Science"},{"key":"859_CR47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/jmv.20575","volume":"78","author":"J Ren","year":"2006","unstructured":"Ren, J. et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy. J. Med. Virol. 78, 551\u2013560 (2006).","journal-title":"J. Med. Virol."},{"key":"859_CR48","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1021\/acsmedchemlett.7b00288","volume":"8","author":"X Li","year":"2017","unstructured":"Li, X. et al. Design, synthesis, and evaluation of tetrahydropyrrolo[1,2-c]pyrimidines as capsid assembly inhibitors for HBV treatment. ACS Med Chem. Lett. 8, 969\u2013974 (2017).","journal-title":"ACS Med Chem. Lett."},{"key":"859_CR49","doi-asserted-by":"publisher","first-page":"8609","DOI":"10.1128\/JVI.76.17.8609-8620.2002","volume":"76","author":"K Kakimi","year":"2002","unstructured":"Kakimi, K. et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 76, 8609\u20138620 (2002).","journal-title":"J. Virol."},{"key":"859_CR50","doi-asserted-by":"publisher","first-page":"14913","DOI":"10.1073\/pnas.0406282101","volume":"101","author":"MT Chen","year":"2004","unstructured":"Chen, M. T. et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl Acad. Sci. USA 101, 14913\u201314918 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"859_CR51","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215\u20134225 (2007).","journal-title":"J. Virol."},{"key":"859_CR52","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1128\/JVI.00561-08","volume":"82","author":"N Chai","year":"2008","unstructured":"Chai, N. et al. Properties of subviral particles of hepatitis B virus. J. Virol. 82, 7812\u20137817 (2008).","journal-title":"J. Virol."},{"key":"859_CR53","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim, G. A. et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63, 1325\u20131332 (2014).","journal-title":"Gut"},{"key":"859_CR54","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"HL Chan","year":"2010","unstructured":"Chan, H. L. et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52, 1232\u20131241 (2010).","journal-title":"Hepatology"},{"key":"859_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0021-9150(01)00679-7","volume":"162","author":"D Gaffney","year":"2002","unstructured":"Gaffney, D. et al. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis 162, 33\u201343 (2002).","journal-title":"Atherosclerosis"},{"key":"859_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen, M. F. et al. RNA interference therapy With ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology 72, 19\u201331 (2020).","journal-title":"Hepatology"},{"key":"859_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561\u2013569 (2008).","journal-title":"Nat. Biotechnol."},{"key":"859_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","volume":"107","author":"J Heyes","year":"2005","unstructured":"Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control Release 107, 276\u2013287 (2005).","journal-title":"J. Control Release"},{"key":"859_CR59","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.omtn.2017.10.003","volume":"9","author":"X Song","year":"2017","unstructured":"Song, X. et al. Site-specific modification using the 2\u2019-methoxyethyl group improves the specificity and activity of siRNAs. Mol. Ther. Nucleic Acids 9, 242\u2013250 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"859_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas, M. M. et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat. Commun. 9, 723 (2018).","journal-title":"Nat. Commun."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00859-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T12:04:49Z","timestamp":1676117089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1038\/s41392-021-00859-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors, except X.J.L., are employees or consultants of Suzhou Ribo Life Science Co. Ltd. X.J.L. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}